Lecraza (lazertinib)

About Yuhan

Yuhan's mission is to develop innovative medicines that improve human and animal health, guided by its founder's revolutionary principle that corporate profits are a public trust. Its landmark achievement is the global success of 'Lecraza' (lazertinib), a third-generation EGFR-TKI for NSCLC, developed in partnership with Janssen, which has transformed it into a recognized oncology innovator. The company's strategy leverages deep internal R&D in small molecules, biologics, and drug delivery, amplified by a proactive open innovation model to in-license and co-develop high-potential candidates. This approach, combined with its robust commercial infrastructure, positions Yuhan for sustained growth across Asia and global markets.

Therapeutic Areas